{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T20:56:32Z","timestamp":1779224192453,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100021711","name":"Bayerisches Staatsministerium f\u00fcr Wissenschaft und Kunst","doi-asserted-by":"publisher","award":["109753"],"award-info":[{"award-number":["109753"]}],"id":[{"id":"10.13039\/501100021711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113472"],"award-info":[{"award-number":["70113472"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70112463"],"award-info":[{"award-number":["70112463"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["WE4632\/4-1,SFB TRR305-B09"],"award-info":[{"award-number":["WE4632\/4-1,SFB TRR305-B09"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KL 1233\/2-1,SFB TRR 305-Z02"],"award-info":[{"award-number":["KL 1233\/2-1,SFB TRR 305-Z02"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB TRR 305-B13"],"award-info":[{"award-number":["SFB TRR 305-B13"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006463","name":"Bayerisches Staatsministerium f\u00fcr Wirtschaft und Medien, Energie und Technologie","doi-asserted-by":"publisher","award":["20-3410.1-1-1,20-3410.1-1-2"],"award-info":[{"award-number":["20-3410.1-1-1,20-3410.1-1-2"]}],"id":[{"id":"10.13039\/501100006463","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","award":["2020.129.1"],"award-info":[{"award-number":["2020.129.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Relapse in melanoma after targeted or immune therapy necessitates the rapid identification of effective alternatives. To address this gap, we investigated whether the timely generation of preclinical models for functional drug testing could reveal additional therapeutic options. Our study focused on: (i) the feasibility of generating in vivo and in vitro models from melanoma lymph node (LN)-derived disseminated cancer cells (DCCs) before relapse, (ii) the implementation of preclinical models to identify therapeutic alternatives, and (iii) the ability to detect patients who could benefit from early functional in vitro drug testing. Successful model generation was significantly associated with DCC quantity, LN origin, and mortality risk. All patient-derived xenograft models were available before patient death and, in 82% of cases, before relapse. Proof-of-concept in vitro drug screening using 315 anti-cancer drugs identified additional candidates, and coculture of DCCs and LN cells revealed specific T-cell activation and responses to immunotherapy. Our data establish a process for selecting melanoma patients at high risk of progression, enabling the timely generation of patient-derived models to support functionally guided treatment decisions at relapse.<\/jats:p>","DOI":"10.1038\/s44321-025-00339-8","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T10:18:36Z","timestamp":1764929916000},"page":"297-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Micrometastasis-derived models enable drug testing for early-stage, high-risk melanoma patients"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9313-5057","authenticated-orcid":false,"given":"Kathrin","family":"Weidele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1647-4804","authenticated-orcid":false,"given":"Christian","family":"Werno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7716-2044","authenticated-orcid":false,"given":"Steffi","family":"Treitschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Botteron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9863-1772","authenticated-orcid":false,"given":"Martin","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Scheitler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"W\u00f6hrl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zbigniew","family":"Czyz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Feliciello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7480-8828","authenticated-orcid":false,"given":"Florian","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adithi","family":"Ravikumar Varadarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5041-2925","authenticated-orcid":false,"given":"Jens","family":"Warfsmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Materna-Reichelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2874-3306","authenticated-orcid":false,"given":"Marie","family":"Katzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Schreieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parvaneh","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hedayatollah","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamran","family":"Honarnejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Haferkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Werner-Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7128-1725","authenticated-orcid":false,"given":"Christoph A","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"339_CR1","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1200\/JCO.2015.64.9673","volume":"34","author":"A Angelis","year":"2016","unstructured":"Angelis A, Kanavos P (2016) Critique of the American Society of Clinical Oncology Value Assessment Framework for Cancer Treatments: putting methodologic robustness first. J Clin Oncol 34:2935\u20132936","journal-title":"J Clin Oncol"},{"key":"339_CR2","unstructured":"Broad Institute (2019) Picard Toolkit. GitHub Repository. http:\/\/broadinstitute.github.io\/picard"},{"key":"339_CR3","doi-asserted-by":"publisher","first-page":"10425","DOI":"10.1158\/0008-5472.CAN-06-2126","volume":"66","author":"D Chen","year":"2006","unstructured":"Chen D, Cui QC, Yang H, Dou QP (2006) Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 66:10425\u201310433","journal-title":"Cancer Res"},{"key":"339_CR4","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1093\/bioinformatics\/btu558","volume":"30","author":"J Chu","year":"2014","unstructured":"Chu J, Sadeghi S, Raymond A, Jackman SD, Nip KM, Mar R, Mohamadi H, Butterfield YS, Robertson AG, Birol I (2014) BioBloom tools: fast, accurate and memory-efficient host species sequence screening using bloom filters. Bioinformatics 30:3402\u20133404","journal-title":"Bioinformatics"},{"key":"339_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/fly.19695","volume":"6","author":"P Cingolani","year":"2012","unstructured":"Cingolani P, Platts A, Le Wang L, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM (2012) A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly 6:80\u201392","journal-title":"Fly"},{"key":"339_CR6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41586-023-06225-y","volume":"619","author":"SA Cohen","year":"2023","unstructured":"Cohen SA, Liu MC, Aleshin A (2023) Practical recommendations for using ctDNA in clinical decision making. Nature 619:259\u2013268","journal-title":"Nature"},{"key":"339_CR7","doi-asserted-by":"publisher","first-page":"e85907","DOI":"10.1371\/journal.pone.0085907","volume":"9","author":"ZT Czy\u017c","year":"2014","unstructured":"Czy\u017c ZT, Hoffmann M, Schlimok G, Polzer B, Klein CA (2014) Reliable single cell array CGH for clinical samples. PLoS ONE 9:e85907","journal-title":"PLoS ONE"},{"key":"339_CR41","doi-asserted-by":"crossref","unstructured":"Dratkiewicz E, Simiczyjew A, Pietraszek-Gremplewicz K, Mazurkiewicz J, Nowak D (2019) Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment. Int J Mol Sci 21(1):113","DOI":"10.3390\/ijms21010113"},{"key":"339_CR8","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/nm.3954","volume":"21","author":"H Gao","year":"2015","unstructured":"Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Singh M, Zhang C, Schnell C, Yang G, Zhang Y et al (2015) High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med 21:1318\u20131325","journal-title":"Nat Med"},{"key":"339_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115152","volume":"215","author":"C Garbe","year":"2025","unstructured":"Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Brochez L, Del Marmol V et al (2025) European consensus-based interdisciplinary guideline for melanoma. Part 1: diagnostics - update 2024. Eur J Cancer 215:115152","journal-title":"Eur J Cancer"},{"key":"339_CR10","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.semcancer.2019.07.022","volume":"60","author":"Y Garcia-Mayea","year":"2020","unstructured":"Garcia-Mayea Y, Mir C, Masson F, Paciucci R, LLeonart ME (2020) Insights into new mechanisms and models of cancer stem cell multidrug resistance. Semin Cancer Biol 60:166\u2013180","journal-title":"Semin Cancer Biol"},{"key":"339_CR11","unstructured":"Garrison E, Marth G (2012) Haplotype-based variant detection from short-read sequencing. arXiv:1207.3907"},{"key":"339_CR12","first-page":"472","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA et al (2017) Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67:472\u2013492","journal-title":"CA Cancer J Clin"},{"key":"339_CR14","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/s43018-025-00963-w","volume":"6","author":"S Guetter","year":"2025","unstructured":"Guetter S, K\u00f6nig C, Koerkel-Qu H, Markiewicz A, Scheitler S, Katzer M, Berneburg M, Renner P, Cucuruz B, Guttenberger L et al (2025) MCSP+ metastasis founder cells activate immunosuppression early in human melanoma metastatic colonization. Nat Cancer 6:1017\u20131034","journal-title":"Nat Cancer"},{"key":"339_CR15","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature20785","volume":"540","author":"H Hosseini","year":"2016","unstructured":"Hosseini H, Obradovi\u0107 MMS, Hoffmann M, Harper KL, Sosa MS, Werner-Klein M, Nanduri LK, Werno C, Ehrl C, Maneck M et al (2016) Early dissemination seeds metastasis in breast cancer. Nature 540:552\u2013558","journal-title":"Nature"},{"key":"339_CR16","doi-asserted-by":"publisher","first-page":"6070","DOI":"10.1158\/1078-0432.CCR-09-1035","volume":"15","author":"K Iljin","year":"2009","unstructured":"Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, Grafstr\u00f6m RC, Per\u00e4l\u00e4 M, Kallioniemi O (2009) High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res 15:6070\u20136078","journal-title":"Clin Cancer Res"},{"key":"339_CR17","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1093\/annonc\/mdx416","volume":"28","author":"E Izumchenko","year":"2017","unstructured":"Izumchenko E, Paz K, Ciznadija D, Sloma I, Katz A, Vasquez-Dunddel D, Ben-Zvi I, Stebbing J, McGuire W, Harris W et al (2017) Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann Oncol 28:2595\u20132605","journal-title":"Ann Oncol"},{"key":"339_CR18","unstructured":"Joint Genome Institute-JGI DataScience (2019) BBTools software suite. https:\/\/jgi.doe.gov\/data-and-tools\/software-tools\/bbtools\/"},{"key":"339_CR19","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"Kim S, Scheffler K, Halpern AL, Bekritsky MA, Noh E, K\u00e4llberg M, Chen X, Kim Y, Beyter D, Krusche P et al (2018) Strelka2: fast and accurate calling of germline and somatic variants. Nat Methods 15:591\u2013594","journal-title":"Nat Methods"},{"key":"339_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221134087","volume":"14","author":"I Kobeissi","year":"2022","unstructured":"Kobeissi I, Tarhini AA (2022) Systemic adjuvant therapy for high-risk cutaneous melanoma. Ther Adv Med Oncol 14:17588359221134087","journal-title":"Ther Adv Med Oncol"},{"key":"339_CR21","first-page":"1","volume":"42","author":"CD Lao","year":"2022","unstructured":"Lao CD, Khushalani NI, Angeles C, Petrella TM (2022) Current state of adjuvant therapy for melanoma: less is more, or more is better?. Am Soc Clin Oncol Educ Book 42:1\u20137","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"339_CR22","unstructured":"Li H (2013) Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv:1303.3997"},{"key":"339_CR23","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41587-019-0037-y","volume":"37","author":"Y Liu","year":"2019","unstructured":"Liu Y, Mi Y, Mueller T, Kreibich S, Williams EG, van Drogen A, Borel C, Frank M, Germain P-L, Bludau I et al (2019) Multi-omic measurements of heterogeneity in HeLa cells across laboratories. Nat Biotechnol 37:314\u2013322","journal-title":"Nat Biotechnol"},{"key":"339_CR24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke JJ, Flaherty KT, Ribas A, Long GV (2017) Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 14:463\u2013482","journal-title":"Nat Rev Clin Oncol"},{"key":"339_CR25","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Swanton C (2017) Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168:613\u2013628","journal-title":"Cell"},{"key":"339_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, Flicek P, Cunningham F (2016) The Ensembl variant effect predictor. Genome Biol 17:122","journal-title":"Genome Biol"},{"key":"339_CR43","doi-asserted-by":"crossref","unstructured":"Misek SA, Foda BM, Dexheimer TS, Akram M, Conrad SE, Schmidt JC, Neubig RR, Gallo KA (2022) BRAF Inhibitor Resistance Confers Increased Sensitivity to Mitotic Inhibitors. Front Oncol 12:766794","DOI":"10.3389\/fonc.2022.766794"},{"key":"339_CR27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","volume":"16","author":"K Pantel","year":"2019","unstructured":"Pantel K, Alix-Panabi\u00e8res C (2019) Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol 16:409\u2013424","journal-title":"Nat Rev Clin Oncol"},{"key":"339_CR28","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.cels.2020.08.012","volume":"11","author":"R Quevedo","year":"2020","unstructured":"Quevedo R, Smirnov P, Tkachuk D, Ho C, El-Hachem N, Safikhani Z, Pugh TJ, Haibe-Kains B (2020) Assessment of genetic drift in large pharmacogenomic studies. Cell Syst 11:393\u2013401.e2","journal-title":"Cell Syst"},{"key":"339_CR29","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/nature07567","volume":"456","author":"E Quintana","year":"2008","unstructured":"Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ (2008) Efficient tumour formation by single human melanoma cells. Nature 456:593\u2013598","journal-title":"Nature"},{"key":"339_CR30","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","volume":"24","author":"M Russo","year":"2024","unstructured":"Russo M, Chen M, Mariella E, Peng H, Rehman SK, Sancho E, Sogari A, Toh TS, Balaban NQ, Batlle E et al (2024) Cancer drug-tolerant persister cells: from biological questions to clinical opportunities. Nat Rev Cancer 24:694\u2013717","journal-title":"Nat Rev Cancer"},{"key":"339_CR31","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75:10\u201345","journal-title":"CA Cancer J Clin"},{"key":"339_CR32","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S0140-6736(09)61397-0","volume":"374","author":"JF Thompson","year":"2009","unstructured":"Thompson JF, Scolyer RA, Kefford RF (2009) Cutaneous melanoma in the era of molecular profiling. Lancet 374:362\u2013365","journal-title":"Lancet"},{"key":"339_CR33","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1002\/ijc.34658","volume":"153","author":"S Treitschke","year":"2023","unstructured":"Treitschke S, Weidele K, Varadarajan AR, Feliciello G, Warfsmann J, Vorbeck S, Polzer B, Botteron C, Hoffmann M, Dechand V et al (2023) Ex vivo expansion of lung cancer-derived disseminated cancer cells from lymph nodes identifies cells associated with metastatic progression. Int J Cancer 153:1854\u20131867","journal-title":"Int J Cancer"},{"key":"339_CR34","doi-asserted-by":"publisher","first-page":"e1001604","DOI":"10.1371\/journal.pmed.1001604","volume":"11","author":"A Ulmer","year":"2014","unstructured":"Ulmer A, Dietz K, Hodak I, Polzer B, Scheitler S, Yildiz M, Czyz Z, Lehnert P, Fehm T, Hafner C et al (2014) Quantitative measurement of melanoma spread in sentinel lymph nodes and survival. PLoS Med 11:e1001604","journal-title":"PLoS Med"},{"key":"339_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.12.002","volume":"91","author":"A Ulmer","year":"2018","unstructured":"Ulmer A, Dietz K, Werner-Klein M, H\u00e4fner H-M, Schulz C, Renner P, Weber F, Breuninger H, R\u00f6cken M, Garbe C et al (2018) The sentinel lymph node spread determines quantitatively melanoma seeding to non-sentinel lymph nodes and survival. Eur J Cancer 91:1\u201310","journal-title":"Eur J Cancer"},{"key":"339_CR36","doi-asserted-by":"publisher","first-page":"5425","DOI":"10.1158\/1078-0432.CCR-04-1995","volume":"11","author":"A Ulmer","year":"2005","unstructured":"Ulmer A, Fischer JR, Schanz S, Sotlar K, Breuninger H, Dietz K, Fierlbeck G, Klein CA (2005) Detection of melanoma cells displaying multiple genomic changes in histopathologically negative sentinel lymph nodes. Clin Cancer Res 11:5425\u20135432","journal-title":"Clin Cancer Res"},{"key":"339_CR37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2022.06.054","volume":"174","author":"A Ulmer","year":"2022","unstructured":"Ulmer A, Pfefferle V, Walter V, Granai M, Keim U, Fend F, Sulyok M, B\u00f6sm\u00fcller H (2022) Reporting of melanoma cell densities in the sentinel node refines outcome prediction. Eur J Cancer 174:121\u2013130","journal-title":"Eur J Cancer"},{"key":"339_CR38","doi-asserted-by":"crossref","first-page":"11.10.1","DOI":"10.1002\/0471250953.bi1110s43","volume":"43","author":"GA van der Auwera","year":"2013","unstructured":"van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, Jordan T, Shakir K, Roazen D, Thibault J et al (2013) From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinforma 43:11.10.1\u201311.10.33","journal-title":"Curr Protoc Bioinforma"},{"key":"339_CR39","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38:e164","journal-title":"Nucleic Acids Res"},{"key":"339_CR42","doi-asserted-by":"crossref","unstructured":"Wang B, Zhang W, Zhang G, Kwong L, Lu H, Tan J, Sadek N, Xiao M, Zhang J, Labrie M et al (2021) Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Oncogene 40:5590\u20135599","DOI":"10.1038\/s41388-021-01911-5"},{"key":"339_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02674-y","volume":"9","author":"M Werner-Klein","year":"2018","unstructured":"Werner-Klein M, Scheitler S, Hoffmann M, Hodak I, Dietz K, Lehnert P, Naimer V, Polzer B, Treitschke S, Werno C et al (2018) Genetic alterations driving metastatic colony formation are acquired outside of the primary tumour in melanoma. Nat Commun 9:595","journal-title":"Nat Commun"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-025-00339-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-025-00339-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-025-00339-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:45:46Z","timestamp":1779065146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-025-00339-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,15]]}},"alternative-id":["339"],"URL":"https:\/\/doi.org\/10.1038\/s44321-025-00339-8","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}